Multiple Sclerosis Drugs - Tanzania

Tanzania

The Multiple Sclerosis Drugs market in Tanzania is estimated to reach a revenue of US$3.99m in 2024.
It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 2.02%, resulting in a market volume of US$4.41m by 2029.
When compared globally, United States is expected to generate the highest revenue with US$11,770.00m in 2024.
Tanzania has seen an increase in the availability and affordability of multiple sclerosis drugs, improving access to treatment for patients in the country.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Tanzania has been steadily growing in recent years.

Customer preferences: Patients with Multiple Sclerosis in Tanzania are increasingly seeking treatments that offer long-term benefits and minimal side effects. They are also looking for medications that are affordable and easily accessible. Due to the high cost of branded drugs, many patients are turning to generic drugs as a more affordable option.

Trends in the market: One of the main trends in the Multiple Sclerosis Drugs market in Tanzania is the increasing availability of generic drugs. This has made treatment more affordable and accessible for patients. Another trend is the growing use of disease-modifying therapies, which can slow down the progression of the disease and improve quality of life for patients.

Local special circumstances: The healthcare system in Tanzania is still developing, and access to healthcare services can be limited in certain areas. This can make it difficult for patients with Multiple Sclerosis to receive the treatment they need. Additionally, there is a lack of awareness about Multiple Sclerosis among the general public and healthcare professionals, which can result in delayed diagnosis and treatment.

Underlying macroeconomic factors: The economy in Tanzania has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. However, the healthcare system in Tanzania is still underfunded and understaffed, which can limit access to healthcare services for many patients. Additionally, the high cost of branded drugs can make it difficult for patients to afford the treatment they need. As a result, the availability of affordable generic drugs is becoming increasingly important in the Multiple Sclerosis Drugs market in Tanzania.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.